Prescription Medicines
Valtrep Tab. 160mg
- Product Category
- ARB antihypertensive drugs
- Active Ingredients
- valsartan
- Appearance
- A grayish-orange, oval, film-coated tablet.
- Reimbursement Code
- 648102940
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Valsartan (USP) ---------- 160mg
- Additives (tar color aluminum lake): Blue No. 2, Yellow No. 5
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry yellow (03B62479), low-substituted hydroxypropyl cellulose, colloidal silicon dioxide, povidone
2. Efficacy/Effectiveness
1. Essential hypertension
2. Heart failure - Heart failure intolerant to ACE inhibitors (NYHA class Ⅱ ~ Ⅳ)
3. Reduced risk of death after myocardial infarction - in clinically stable patients with signs, symptoms, or radiological left ventricular dysfunction and/or left ventricular systolic dysfunction.
Reduced risk of death after myocardial infarction
3. Usage/Dosage
1. Essential hypertension - Take with water during meals or between meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning).
1) Adults: Regardless of gender or race, oral administration of 80 mg once a day is recommended as valsartan. The blood pressure lowering effect appears gradually within 2 weeks and the maximum effect occurs after 4 weeks.
indicates. For patients with poor blood pressure control, the dose may be increased to 160 mg per day or diuretics may be administered together. If additional blood pressure lowering is needed,
The dose can be increased up to 320 mg per day.
2) Elderly (age 75 or older): Start taking this drug at 40mg once a day.
3) Patients with renal impairment:
(1) Creatinine clearance rate 20 ~ 50mL/min: No dosage adjustment is necessary.
(2) Creatinine clearance rate 10 to 20 mL/min: Begin administration of this drug at 40 mg once a day.
(3) Creatinine clearance less than 10mL/min and dialysis patients: Do not administer this drug.
4) Patients with insufficient fluid in the blood: For patients with insufficient fluid in the blood (e.g., patients taking high doses of diuretics and unable to reduce the dose), take this drug at 40 mg once a day.
Start dosing.
5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, treatment should begin with 40 mg of this drug once a day, and the dosage should not exceed 80 mg per day. Severe liver failure, cirrhosis,
This drug should not be administered to patients with cholestasis.
6) Children: Safety and effectiveness have not been established in children and adolescents under 18 years of age.
2. Heart failure
- Adults: The recommended starting dose is 40 mg orally twice a day, and can be increased to 80 mg or 160 mg once. When administered concurrently with diuretics, the dose of diuretics may be reduced.
must be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple coadministration of this drug with ACE inhibitors and beta blockers is not recommended.
3. Reduced risk of death after myocardial infarction
- Adults: Administration can begin within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice a day, and then increase over several weeks.
This drug is administered at a dose of 40mg, 80mg, or 160mg twice a day, and the dose is increased considering the patient's tolerance.
If symptoms of low blood pressure or renal failure occur, consider reducing the dose.
This drug can also be administered to patients who are being treated with other administration methods (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins) after myocardial infarction.
However, combined use with ACE inhibitors is not recommended.
4. Patients with renal impairment: No dose adjustment is necessary if the creatinine clearance rate is 10 mL/min or more, but there is no experience of use in creatinine clearance less than 10 mL/min and dialysis patients.
Therefore, do not administer this drug.
5. Patients with hepatic impairment: It is recommended that the daily dose of this drug for patients with mild to moderate hepatic impairment do not exceed 80 mg per day. When administering more than 80mg per day,
When increasing the dose, it must be considered whether the benefits of treatment outweigh the risks. This drug should not be administered to patients with severe liver impairment, cirrhosis, or cholestasis.
6. Children: Safety and effectiveness have not been established in children and adolescents under 18 years of age.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) are administered to pregnant women, damage and even death may occur in the fetus and newborn. Dozens of such cases have been reported worldwide, even in patients taking ACE inhibitors. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately (see ‘Administration for pregnant and lactating women’ section).
2. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with severe liver impairment, cirrhosis, biliary obstruction, or cholestasis
4) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
5) Patients with severe renal impairment (creatinine clearance less than 10 mL/min) (no experience with use)
6) Patients with primary hyperaldosteronism (This drug is not administered to patients with primary hyperaldosteronism because the renin-angiotensin-aldosterone system is not activated.)
7) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
3. Administer with caution to the following patients (cases):
1) Elderly people
2) Patients with hyperkalemia or patients prone to elevated serum potassium levels
3) Patients with mild to moderate hepatic impairment (It is recommended that the daily dose of this drug for patients with mild to moderate hepatic impairment does not exceed 80 mg.)
4) Patients with aortic and mitral valve stenosis or obstructive hypertrophic cardiomyopathy
5) Patients with ischemic heart disease, ischemic cardiovascular disease, and cerebrovascular disorder (excessive drop in blood pressure can cause myocardial infarction or stroke due to cerebral blood flow failure.)
6) Patients with sodium or volume deficiency, such as those receiving high doses of diuretics (hypotension may rarely occur in the early stages of treatment with this drug).
7) Patients with bilateral or unilateral renal artery stenosis (If other drugs that affect the renin-angiotensin-aldosterone system are administered, blood urea and serum creatinine may increase, so monitoring is recommended for safety reasons.)
8) Patients after heart failure or myocardial infarction: Administration of ACE inhibitors or angiotensin receptor antagonists (ARBs) to patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system (RAAS) (e.g., severe heart failure) is associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
9) Patients undergoing hemodialysis or patients undergoing strict low-salt therapy (starting with a low dose and increasing the dose should be done slowly while carefully observing the patient's condition.)
10) Patients within 24 hours before surgery
11) Dual blockade of the renin-angiotensin-aldosterone system (RAAS): Concurrent use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor antagonists (ARB), ACE inhibitors, or aliskiren, is not recommended.
4. Adverse reactions
1) Patients with high blood pressure
The overall incidence of adverse reactions was compared in placebo-controlled trials including 2,316 patients with hypertension treated with this drug. The following table of adverse reactions is based on 10 clinical trials in which patients were treated with various doses of valsartan (10 to 320 mg) for more than 12 weeks, with 1,281 and 660 of 2,316 receiving 80 mg and 160 mg, respectively. Because the incidence of adverse reactions was independent of the dose, treatment period, gender, age, and race of this drug, all adverse reactions with an incidence of more than 1% were included in the following table, regardless of causal relationship with the test drug. (Refer to table and attached document)
2) Patients with heart failure
In a short-term, double-blind study including the 4-month Valsartan Heart Failure Study (Val-HeFT), the following drug-related adverse reactions were observed more frequently in valsartan-treated patients than in placebo-treated patients, with an incidence of greater than 1%. :
Dizziness, hypotension, orthostatic dizziness, orthostatic hypotension, fatigue, diarrhea, headache, nausea, renal function impairment, hyperkalemia, all patients were treated with polytherapy including diuretics, digitalis, beta blockers or ACE inhibitors for heart failure.
Long-term data from Val-HeFT showed no adverse reactions other than those already known during the short-term study.
3) Patients after myocardial infarction
The results of VALIANT, a multinational, multicenter, double-blind, randomized, control-controlled parallel group study comparing the efficacy and safety of valsartan, captopril, and the long-term administration of valsartan and captopril in high-risk patients after myocardial infarction, showed that the safety of valsartan was consistent with the population (e.g., heart failure patients), the properties of the drug itself, cardiovascular risk factors, and clinical progress of patients treated in the post-myocardial infarction state.
Serious adverse events were primarily cardiovascular and were generally associated with underlying disease. This is also reflected in the all-cause mortality outcome, which was the primary evaluation indicator. Non-fatal serious adverse reactions suspected to be related to the test drug, with a frequency of 0.1% or more and occurring more commonly in the valsartan-treated group than in the captopril-treated group, were reactions related to hyperkalemia, fainting, heart failure, hypotension, angioneurotic edema, and renal function impairment.
The proportion of patients who completely discontinued medication due to adverse reactions was 5.8% in the valsartan treatment group. It was 7.7% in the captopril treatment group.
4) As a result of foreign clinical trials and post-marketing surveillance, the following adverse reactions were observed.
(1) Heart failure, arrhythmia, drowsiness, atrial fibrillation, vomiting, constipation, dry mouth, loss of appetite, malaise
(2) Very rarely, angioedema, redness, itching, serum sickness, other hypersensitivity/allergic reactions including vasculitis, impaired renal function, syncope, epistaxis, hepatitis, arrhythmia, intestinal angioedema.
(3) Interstitial pneumonia: Interstitial pneumonia accompanied by fever, cough, difficulty breathing, and abnormal chest
(4) Hypoglycemia: In particular, as symptoms of hypoglycemia may appear in patients undergoing diabetes treatment, sufficient observation should be conducted and if exhaustion, hunger, cold sweat, hand tremors, decreased concentration, convulsions, or impaired consciousness appear, administration should be stopped and appropriate measures should be taken.
(5) Since adverse reactions such as angioedema (symptoms include swelling of the face, lips, pharynx, tongue, etc.), hepatitis, and renal failure may occur, observe thoroughly, and if symptoms appear, stop administration and take appropriate measures.
(6) Hyperkalemia: Severe hyperkalemia may occur, so observe thoroughly and take appropriate measures immediately if abnormalities are recognized.
(7) Shock, fainting, loss of consciousness: Shock, fainting, and loss of consciousness due to a drop in blood pressure may occur, so observe thoroughly and take appropriate measures immediately if a cold feeling, vomiting, loss of consciousness, etc. appears. In particular, in patients undergoing hemodialysis, strict salt restriction therapy, or taking diuretics, when starting administration at a low dose and increasing the dose, do so slowly while carefully observing the patient's condition.
(8) Rhabdomyolysis: Rhabdomyolysis, which is characterized by muscle pain, weakness, elevation of creatine kinase (CK), and elevation of myoglobin in blood and urine, may occur, so observe sufficiently. In such cases, stop administration and take appropriate measures.
(9) In addition, agranulocytosis, decreased white blood cells, and decreased platelets may occur, so observe thoroughly and take appropriate measures immediately if abnormalities are recognized.
(10) Bullous dermatitis (frequency unknown)
5) Laboratory tests
(1) In 0.8% and 0.4% of patients receiving this drug, red blood cell volume and hemoglobin decreased by more than 20%, respectively. In contrast, a decrease in red blood cell volume and hemoglobin was observed in 0.1% of the placebo group.
(2) Neutropenia was observed in 1.6% of patients treated with ACE inhibitors, whereas it was observed in 1.9% of patients treated with this drug.
(3) In controlled clinical trials targeting patients with hypertension, significant increases in serum creatinine, potassium, and total bilirubin levels were observed. In patients treated with ACE inhibitors, increases of 1.6%, 6.4%, and 12.9% were observed, respectively, while in patients treated with this drug, increases of 0.8%, 4.4%, and 6% were observed, respectively.
Patients with essential hypertension receiving valsartan do not require special laboratory monitoring.
(4) In patients with heart failure, an increase in blood creatinine concentration of more than 50% was observed more often in the valsartan treatment group (3.9%) than in the placebo group (0.9%). Additionally, an increase in blood creatinine concentration of more than 20% was observed more often in the valsartan treatment group (10%) than in the placebo group (5.1%).
In heart failure studies, increases in BUN of more than 50% were observed more often in the valsartan treatment group (16.6%) than in the placebo group (6.3%).
(5) Effect on clinical test values
Occasionally, an increase in liver function test values has been reported, but special monitoring of clinical test values is not necessary for patients with essential hypertension taking this drug.
6) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 1,171 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 7.00% (82/1,171 cases) regardless of causal relationship, and 3.07% (36/1,171 cases) of these were found to have a causal relationship with this drug. BUN increase was the most common at 0.85% (10/1171 cases), followed by headache, dizziness, and cough at 0.43% (5/1171 cases), edema at 0.17% (2/1171 cases), and stiffness and asthenia at 0.09% (1/1171 cases).
As new adverse reactions that did not appear in pre-marketing clinical trials, indigestion, anemia, and tinnitus were reported in two cases each, and hypertonia, decreased motor function, stupor, chest pain, rash, and muscle pain were reported in one case each.
5. General precautions
1) Administration of this drug may cause a rapid temporary drop in blood pressure (accompanied by fainting and loss of consciousness, etc.) after the first administration. In such cases, discontinue administration and take appropriate measures. In addition, especially in the following patients, administration should be started at a low dose and the dose increased slowly while carefully observing the patient's condition.
(1) Patients undergoing hemodialysis
(2) Patients taking diuretics (especially in patients with severe sodium deficiency or volume deficiency, caution may occur in rare cases of symptomatic hypotension).
(3) Patients undergoing strict salt restriction
2) In patients with severe sodium depletion or body fluid depletion due to taking high doses of diuretics, hypotension may rarely occur in the early stages of taking this drug. This depletion of sodium and body fluids before administration of this drug should be corrected by methods such as reducing the diuretic dose. If low blood pressure occurs, have the patient lie down in an upright position and, if necessary, inject physiological saline solution by drip. Continue drug administration after blood pressure stabilizes.
3) Patients with renal artery stenosis: Short-term administration of this drug to 12 patients with renovascular hypertension accompanied by secondary unilateral renal artery stenosis did not induce significant changes in renal hemodynamics, serum creatinine, and BUN. However, when other drugs that affect the renin-angiotensin-aldosterone system are administered to patients with bilateral or unilateral renal artery stenosis, blood urea and serum creatinine may increase, so monitoring is recommended for safety reasons. In patients with bilateral or unilateral renal artery stenosis, there is a risk of rapid deterioration of renal function due to a decrease in renal blood flow and a decrease in glomerular filtration pressure, so administration should be avoided except in cases where treatment is deemed unavoidable.
4) It is recommended that the daily dose of this drug for patients with mild to moderate hepatic impairment do not exceed 80 mg. This drug is mostly excreted in bile as an unchanged form and has a low clearance rate in patients with biliary obstruction, so it is not used in these patients. It has been reported that when this drug is administered to patients with mild to moderate hepatic impairment, the plasma concentration increases approximately twice that of healthy adults.
5) Patients receiving this drug after heart failure or myocardial infarction mainly experience a decrease in blood pressure, but there is no need to discontinue treatment due to persistent symptoms of low blood pressure. Caution should be exercised when initiating treatment in patients with heart failure or after a myocardial infarction.
As a result of inhibition of the renin-angiotensin-aldosterone system, changes in renal function are expected in susceptible patients. Treatment with ACE inhibitors and angiotensin II receptor antagonists in patients with severe heart failure whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Similar results have been reported with this drug. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
Triple therapy of ACE inhibitors, beta-blockers, and valsartan is not recommended in patients with heart failure. This is because simultaneous administration of beta-blockers and ACE inhibitors increases morbidity and mortality due to heart failure.
Increases in BUN, creatinine, and potassium levels have been observed in some heart failure patients. This phenomenon is mainly mild and temporary, and is likely to occur in patients with pre-existing renal damage. Dosage reduction and discontinuation of this drug and/or diuretic should be considered.
6) In patients with hyperkalemia, avoid administration except in cases where treatment is deemed unavoidable as there is a risk of worsening hyperkalemia. Additionally, patients who are prone to elevated serum potassium levels due to kidney dysfunction, diabetes, etc., may develop hyperkalemia, so pay attention to serum potassium levels.
7) There is no experience of use in patients who recently underwent kidney transplantation.
8) As with other antihypertensive drugs, the hypotensive effect may cause dizziness and staggering, so special care must be taken when driving or operating machinery.
9) Intestinal angioedema has been reported in patients receiving angiotensin II receptor antagonists. These patients presented with abdominal pain, nausea, vomiting, and diarrhea. Symptoms resolved after discontinuation of angiotensin II receptor antagonist. If intestinal angioedema is diagnosed, treatment should be discontinued and appropriate monitoring should be conducted until symptoms completely resolve.
6. Interaction
1) There were no clinically significant drug interactions.
There have been clinical trials examining interactions with cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorthiazide, amlodipine, and glibenclamide. When combined with cimetidine, the systemic exposure of valsartan may be increased, and when combined with glibenclamide, the systemic exposure of valsartan may be decreased.
Because this drug is not metabolized to a significant degree, drug-drug interactions due to induction or inhibition of metabolism of the CYP-450 enzyme system are not expected to occur clinically. Although this drug showed high binding to plasma proteins, in vivo studies showed no interaction with highly protein-bound drugs such as diclofenac, furosemide, and warfarin.
2) When using potassium-sparing diuretics (spironolactone, triamterene, amirolide), potassium supplements, potassium-containing salts, or drugs that can increase potassium concentration (e.g., heparin), caution is required as blood potassium concentration may increase or blood creatinine concentration may increase in heart failure patients.
3) When angiotensin II receptor antagonists are used in combination with non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day), non-selective NSAIDs), the blood pressure lowering effect may be reduced. Like ACE inhibitors, combined use of angiotensin II receptor antagonists and NSAIDs can worsen renal function, cause acute renal failure, and increase serum potassium. Caution must be exercised when using together, especially in the elderly or patients with reduced effective blood volume (including patients receiving diuretic treatment). After starting combination treatment, patients should be provided with adequate fluids and renal function should be monitored periodically.
4) A reversible increase in serum lithium concentration and toxicity has been reported with co-administration of lithium drugs and ACE inhibitors or angiotensin II receptor antagonists, including this drug. Therefore, monitoring of serum lithium concentrations is recommended during coadministration. The risk of lithium toxicity may increase if thiazide diuretics are additionally used.
5) Transporters: In vitro studies using human liver tissue showed that valsartan is a substrate for the liver uptake transporter OATP1B1 and the liver efflux transporter MRP2. Coadministration with uptake transporter inhibitors (rifampicin, cyclosporine) or efflux transporter inhibitors (ritonavir) may increase systemic exposure of valsartan.
6) Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin receptor antagonists, ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving this drug concomitantly with other drugs that act on RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2).
7. Administration to pregnant and lactating women
1) Because of the mechanism of action of angiotensin II receptor antagonists, the risk to the fetus cannot be ignored. In pregnant women exposed to ACE inhibitors (a specific class of drugs that act on the renin-angiotensin-aldosterone system) during the second or third trimester of pregnancy, they have been associated with fetal and neonatal harm, including fetal and neonatal hypotension, hyperkalemia, neonatal cranial hypoplasia, urinary retention and/or anuria, reversible or irreversible renal failure, intrauterine growth retardation, and death. Oligohydramnios, presumed to be due to decreased fetal renal function, was reported, and oligohydramnios was associated with fetal limb contractures, craniofacial malformations, and pulmonary hypoplasia. Retrospective data suggest that use of ACE inhibitors in the first trimester of pregnancy is associated with a potential risk of birth defects. Additionally, although it is not clear whether this drug is caused by it, there are reports of prematurity, intrauterine growth retardation, and patent ductus arteriosus. There have been reports of spontaneous abortion, oligohydramnios, and renal dysfunction in newborns when pregnant women accidentally took valsartan. Like other drugs that act directly on the renin-angiotensin-aldosterone system, this drug should not be used by women who are pregnant or planning to become pregnant, and if pregnancy is confirmed while taking the drug, the drug should be discontinued immediately. When prescribing drugs that act on the renin-angiotensin-aldosterone system to women who may become pregnant, doctors should inform them of the potential risks of these drugs during pregnancy. If a pregnant woman has been exposed to angiotensin II receptor antagonists beyond the second trimester, fetal renal function and cranial ultrasound examination is recommended. Additionally, neonates who have been exposed to this drug in utero should be closely monitored for sufficient urination, hyperkalemia, and blood pressure.
2) It is not known whether this drug is secreted in breast milk, but in experiments on rats, secretion of this drug in breast milk was confirmed, so it is not recommended for nursing mothers to use this drug. Avoid administering this drug to breastfeeding women, and if administration is unavoidable, breast-feeding should be discontinued.
3) There is no information about the effects of this drug on human fertility. Studies in rats showed no effects of valsartan on fertility.
8. Administration to children
Safety and efficacy in children and adolescents under 18 years of age have not been established.
9. Administration to elderly people
In the case of elderly people, it is generally considered undesirable to lower blood pressure excessively due to the risk of cerebral infarction, etc., so administration should be done carefully while observing the patient's condition, such as starting from a low dose. Pharmacokinetic tests on elderly people showed that the blood concentration of this drug was higher than that of non-elderly people.
10. Treatment in case of overdose
Although there is no experience with overdose of this drug, significant hypotension, decreased consciousness, circulatory collapse and shock, tachycardia, and bradycardia due to parasympathetic nerve stimulation are expected. Immediately after taking the drug, induce vomiting or administer medicinal charcoal. Otherwise, inject physiological saline into a vein. If low blood pressure occurs, the patient should be placed in a supine position and blood volume should be corrected. Hemodialysis does not help.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
12. Others
In preclinical safety tests using multiple species of animals, no systemic toxicity or toxicity to specific organs was observed, except for reproductive toxicity. A decreased survival rate and a slight delay in physical development were observed in the offspring of rats administered 600 mg/kg/day during the last 3 months of pregnancy and lactation. Preclinical safety results were mainly consistent with the pharmacological properties of the drug and had no clinical significance. Mutagenicity, chromosomal abnormality, and carcinogenicity were not observed.
5. How to save
Store in an airtight container below 30℃, avoiding heat and moisture.
6. Packaging unit
30 tablets/bottle
7. Expiration date
36 months from date of manufacture
- Active ingredient: Valsartan (USP) ---------- 160mg
- Additives (tar color aluminum lake): Blue No. 2, Yellow No. 5
- Other additives: Microcrystalline cellulose, magnesium stearate, Opadry yellow (03B62479), low-substituted hydroxypropyl cellulose, colloidal silicon dioxide, povidone
2. Efficacy/Effectiveness
1. Essential hypertension
2. Heart failure - Heart failure intolerant to ACE inhibitors (NYHA class Ⅱ ~ Ⅳ)
3. Reduced risk of death after myocardial infarction - in clinically stable patients with signs, symptoms, or radiological left ventricular dysfunction and/or left ventricular systolic dysfunction.
Reduced risk of death after myocardial infarction
3. Usage/Dosage
1. Essential hypertension - Take with water during meals or between meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning).
1) Adults: Regardless of gender or race, oral administration of 80 mg once a day is recommended as valsartan. The blood pressure lowering effect appears gradually within 2 weeks and the maximum effect occurs after 4 weeks.
indicates. For patients with poor blood pressure control, the dose may be increased to 160 mg per day or diuretics may be administered together. If additional blood pressure lowering is needed,
The dose can be increased up to 320 mg per day.
2) Elderly (age 75 or older): Start taking this drug at 40mg once a day.
3) Patients with renal impairment:
(1) Creatinine clearance rate 20 ~ 50mL/min: No dosage adjustment is necessary.
(2) Creatinine clearance rate 10 to 20 mL/min: Begin administration of this drug at 40 mg once a day.
(3) Creatinine clearance less than 10mL/min and dialysis patients: Do not administer this drug.
4) Patients with insufficient fluid in the blood: For patients with insufficient fluid in the blood (e.g., patients taking high doses of diuretics and unable to reduce the dose), take this drug at 40 mg once a day.
Start dosing.
5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, treatment should begin with 40 mg of this drug once a day, and the dosage should not exceed 80 mg per day. Severe liver failure, cirrhosis,
This drug should not be administered to patients with cholestasis.
6) Children: Safety and effectiveness have not been established in children and adolescents under 18 years of age.
2. Heart failure
- Adults: The recommended starting dose is 40 mg orally twice a day, and can be increased to 80 mg or 160 mg once. When administered concurrently with diuretics, the dose of diuretics may be reduced.
must be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple coadministration of this drug with ACE inhibitors and beta blockers is not recommended.
3. Reduced risk of death after myocardial infarction
- Adults: Administration can begin within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice a day, and then increase over several weeks.
This drug is administered at a dose of 40mg, 80mg, or 160mg twice a day, and the dose is increased considering the patient's tolerance.
If symptoms of low blood pressure or renal failure occur, consider reducing the dose.
This drug can also be administered to patients who are being treated with other administration methods (e.g., thrombolytics, acetylsalicylic acid, beta blockers, and statins) after myocardial infarction.
However, combined use with ACE inhibitors is not recommended.
4. Patients with renal impairment: No dose adjustment is necessary if the creatinine clearance rate is 10 mL/min or more, but there is no experience of use in creatinine clearance less than 10 mL/min and dialysis patients.
Therefore, do not administer this drug.
5. Patients with hepatic impairment: It is recommended that the daily dose of this drug for patients with mild to moderate hepatic impairment do not exceed 80 mg per day. When administering more than 80mg per day,
When increasing the dose, it must be considered whether the benefits of treatment outweigh the risks. This drug should not be administered to patients with severe liver impairment, cirrhosis, or cholestasis.
6. Children: Safety and effectiveness have not been established in children and adolescents under 18 years of age.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) are administered to pregnant women, damage and even death may occur in the fetus and newborn. Dozens of such cases have been reported worldwide, even in patients taking ACE inhibitors. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately (see ‘Administration for pregnant and lactating women’ section).
2. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with severe liver impairment, cirrhosis, biliary obstruction, or cholestasis
4) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
5) Patients with severe renal impairment (creatinine clearance less than 10 mL/min) (no experience with use)
6) Patients with primary hyperaldosteronism (This drug is not administered to patients with primary hyperaldosteronism because the renin-angiotensin-aldosterone system is not activated.)
7) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
3. Administer with caution to the following patients (cases):
1) Elderly people
2) Patients with hyperkalemia or patients prone to elevated serum potassium levels
3) Patients with mild to moderate hepatic impairment (It is recommended that the daily dose of this drug for patients with mild to moderate hepatic impairment does not exceed 80 mg.)
4) Patients with aortic and mitral valve stenosis or obstructive hypertrophic cardiomyopathy
5) Patients with ischemic heart disease, ischemic cardiovascular disease, and cerebrovascular disorder (excessive drop in blood pressure can cause myocardial infarction or stroke due to cerebral blood flow failure.)
6) Patients with sodium or volume deficiency, such as those receiving high doses of diuretics (hypotension may rarely occur in the early stages of treatment with this drug).
7) Patients with bilateral or unilateral renal artery stenosis (If other drugs that affect the renin-angiotensin-aldosterone system are administered, blood urea and serum creatinine may increase, so monitoring is recommended for safety reasons.)
8) Patients after heart failure or myocardial infarction: Administration of ACE inhibitors or angiotensin receptor antagonists (ARBs) to patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system (RAAS) (e.g., severe heart failure) is associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
9) Patients undergoing hemodialysis or patients undergoing strict low-salt therapy (starting with a low dose and increasing the dose should be done slowly while carefully observing the patient's condition.)
10) Patients within 24 hours before surgery
11) Dual blockade of the renin-angiotensin-aldosterone system (RAAS): Concurrent use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor antagonists (ARB), ACE inhibitors, or aliskiren, is not recommended.
4. Adverse reactions
1) Patients with high blood pressure
The overall incidence of adverse reactions was compared in placebo-controlled trials including 2,316 patients with hypertension treated with this drug. The following table of adverse reactions is based on 10 clinical trials in which patients were treated with various doses of valsartan (10 to 320 mg) for more than 12 weeks, with 1,281 and 660 of 2,316 receiving 80 mg and 160 mg, respectively. Because the incidence of adverse reactions was independent of the dose, treatment period, gender, age, and race of this drug, all adverse reactions with an incidence of more than 1% were included in the following table, regardless of causal relationship with the test drug. (Refer to table and attached document)
2) Patients with heart failure
In a short-term, double-blind study including the 4-month Valsartan Heart Failure Study (Val-HeFT), the following drug-related adverse reactions were observed more frequently in valsartan-treated patients than in placebo-treated patients, with an incidence of greater than 1%. :
Dizziness, hypotension, orthostatic dizziness, orthostatic hypotension, fatigue, diarrhea, headache, nausea, renal function impairment, hyperkalemia, all patients were treated with polytherapy including diuretics, digitalis, beta blockers or ACE inhibitors for heart failure.
Long-term data from Val-HeFT showed no adverse reactions other than those already known during the short-term study.
3) Patients after myocardial infarction
The results of VALIANT, a multinational, multicenter, double-blind, randomized, control-controlled parallel group study comparing the efficacy and safety of valsartan, captopril, and the long-term administration of valsartan and captopril in high-risk patients after myocardial infarction, showed that the safety of valsartan was consistent with the population (e.g., heart failure patients), the properties of the drug itself, cardiovascular risk factors, and clinical progress of patients treated in the post-myocardial infarction state.
Serious adverse events were primarily cardiovascular and were generally associated with underlying disease. This is also reflected in the all-cause mortality outcome, which was the primary evaluation indicator. Non-fatal serious adverse reactions suspected to be related to the test drug, with a frequency of 0.1% or more and occurring more commonly in the valsartan-treated group than in the captopril-treated group, were reactions related to hyperkalemia, fainting, heart failure, hypotension, angioneurotic edema, and renal function impairment.
The proportion of patients who completely discontinued medication due to adverse reactions was 5.8% in the valsartan treatment group. It was 7.7% in the captopril treatment group.
4) As a result of foreign clinical trials and post-marketing surveillance, the following adverse reactions were observed.
(1) Heart failure, arrhythmia, drowsiness, atrial fibrillation, vomiting, constipation, dry mouth, loss of appetite, malaise
(2) Very rarely, angioedema, redness, itching, serum sickness, other hypersensitivity/allergic reactions including vasculitis, impaired renal function, syncope, epistaxis, hepatitis, arrhythmia, intestinal angioedema.
(3) Interstitial pneumonia: Interstitial pneumonia accompanied by fever, cough, difficulty breathing, and abnormal chest
(4) Hypoglycemia: In particular, as symptoms of hypoglycemia may appear in patients undergoing diabetes treatment, sufficient observation should be conducted and if exhaustion, hunger, cold sweat, hand tremors, decreased concentration, convulsions, or impaired consciousness appear, administration should be stopped and appropriate measures should be taken.
(5) Since adverse reactions such as angioedema (symptoms include swelling of the face, lips, pharynx, tongue, etc.), hepatitis, and renal failure may occur, observe thoroughly, and if symptoms appear, stop administration and take appropriate measures.
(6) Hyperkalemia: Severe hyperkalemia may occur, so observe thoroughly and take appropriate measures immediately if abnormalities are recognized.
(7) Shock, fainting, loss of consciousness: Shock, fainting, and loss of consciousness due to a drop in blood pressure may occur, so observe thoroughly and take appropriate measures immediately if a cold feeling, vomiting, loss of consciousness, etc. appears. In particular, in patients undergoing hemodialysis, strict salt restriction therapy, or taking diuretics, when starting administration at a low dose and increasing the dose, do so slowly while carefully observing the patient's condition.
(8) Rhabdomyolysis: Rhabdomyolysis, which is characterized by muscle pain, weakness, elevation of creatine kinase (CK), and elevation of myoglobin in blood and urine, may occur, so observe sufficiently. In such cases, stop administration and take appropriate measures.
(9) In addition, agranulocytosis, decreased white blood cells, and decreased platelets may occur, so observe thoroughly and take appropriate measures immediately if abnormalities are recognized.
(10) Bullous dermatitis (frequency unknown)
5) Laboratory tests
(1) In 0.8% and 0.4% of patients receiving this drug, red blood cell volume and hemoglobin decreased by more than 20%, respectively. In contrast, a decrease in red blood cell volume and hemoglobin was observed in 0.1% of the placebo group.
(2) Neutropenia was observed in 1.6% of patients treated with ACE inhibitors, whereas it was observed in 1.9% of patients treated with this drug.
(3) In controlled clinical trials targeting patients with hypertension, significant increases in serum creatinine, potassium, and total bilirubin levels were observed. In patients treated with ACE inhibitors, increases of 1.6%, 6.4%, and 12.9% were observed, respectively, while in patients treated with this drug, increases of 0.8%, 4.4%, and 6% were observed, respectively.
Patients with essential hypertension receiving valsartan do not require special laboratory monitoring.
(4) In patients with heart failure, an increase in blood creatinine concentration of more than 50% was observed more often in the valsartan treatment group (3.9%) than in the placebo group (0.9%). Additionally, an increase in blood creatinine concentration of more than 20% was observed more often in the valsartan treatment group (10%) than in the placebo group (5.1%).
In heart failure studies, increases in BUN of more than 50% were observed more often in the valsartan treatment group (16.6%) than in the placebo group (6.3%).
(5) Effect on clinical test values
Occasionally, an increase in liver function test values has been reported, but special monitoring of clinical test values is not necessary for patients with essential hypertension taking this drug.
6) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 1,171 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 7.00% (82/1,171 cases) regardless of causal relationship, and 3.07% (36/1,171 cases) of these were found to have a causal relationship with this drug. BUN increase was the most common at 0.85% (10/1171 cases), followed by headache, dizziness, and cough at 0.43% (5/1171 cases), edema at 0.17% (2/1171 cases), and stiffness and asthenia at 0.09% (1/1171 cases).
As new adverse reactions that did not appear in pre-marketing clinical trials, indigestion, anemia, and tinnitus were reported in two cases each, and hypertonia, decreased motor function, stupor, chest pain, rash, and muscle pain were reported in one case each.
5. General precautions
1) Administration of this drug may cause a rapid temporary drop in blood pressure (accompanied by fainting and loss of consciousness, etc.) after the first administration. In such cases, discontinue administration and take appropriate measures. In addition, especially in the following patients, administration should be started at a low dose and the dose increased slowly while carefully observing the patient's condition.
(1) Patients undergoing hemodialysis
(2) Patients taking diuretics (especially in patients with severe sodium deficiency or volume deficiency, caution may occur in rare cases of symptomatic hypotension).
(3) Patients undergoing strict salt restriction
2) In patients with severe sodium depletion or body fluid depletion due to taking high doses of diuretics, hypotension may rarely occur in the early stages of taking this drug. This depletion of sodium and body fluids before administration of this drug should be corrected by methods such as reducing the diuretic dose. If low blood pressure occurs, have the patient lie down in an upright position and, if necessary, inject physiological saline solution by drip. Continue drug administration after blood pressure stabilizes.
3) Patients with renal artery stenosis: Short-term administration of this drug to 12 patients with renovascular hypertension accompanied by secondary unilateral renal artery stenosis did not induce significant changes in renal hemodynamics, serum creatinine, and BUN. However, when other drugs that affect the renin-angiotensin-aldosterone system are administered to patients with bilateral or unilateral renal artery stenosis, blood urea and serum creatinine may increase, so monitoring is recommended for safety reasons. In patients with bilateral or unilateral renal artery stenosis, there is a risk of rapid deterioration of renal function due to a decrease in renal blood flow and a decrease in glomerular filtration pressure, so administration should be avoided except in cases where treatment is deemed unavoidable.
4) It is recommended that the daily dose of this drug for patients with mild to moderate hepatic impairment do not exceed 80 mg. This drug is mostly excreted in bile as an unchanged form and has a low clearance rate in patients with biliary obstruction, so it is not used in these patients. It has been reported that when this drug is administered to patients with mild to moderate hepatic impairment, the plasma concentration increases approximately twice that of healthy adults.
5) Patients receiving this drug after heart failure or myocardial infarction mainly experience a decrease in blood pressure, but there is no need to discontinue treatment due to persistent symptoms of low blood pressure. Caution should be exercised when initiating treatment in patients with heart failure or after a myocardial infarction.
As a result of inhibition of the renin-angiotensin-aldosterone system, changes in renal function are expected in susceptible patients. Treatment with ACE inhibitors and angiotensin II receptor antagonists in patients with severe heart failure whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Similar results have been reported with this drug. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
Triple therapy of ACE inhibitors, beta-blockers, and valsartan is not recommended in patients with heart failure. This is because simultaneous administration of beta-blockers and ACE inhibitors increases morbidity and mortality due to heart failure.
Increases in BUN, creatinine, and potassium levels have been observed in some heart failure patients. This phenomenon is mainly mild and temporary, and is likely to occur in patients with pre-existing renal damage. Dosage reduction and discontinuation of this drug and/or diuretic should be considered.
6) In patients with hyperkalemia, avoid administration except in cases where treatment is deemed unavoidable as there is a risk of worsening hyperkalemia. Additionally, patients who are prone to elevated serum potassium levels due to kidney dysfunction, diabetes, etc., may develop hyperkalemia, so pay attention to serum potassium levels.
7) There is no experience of use in patients who recently underwent kidney transplantation.
8) As with other antihypertensive drugs, the hypotensive effect may cause dizziness and staggering, so special care must be taken when driving or operating machinery.
9) Intestinal angioedema has been reported in patients receiving angiotensin II receptor antagonists. These patients presented with abdominal pain, nausea, vomiting, and diarrhea. Symptoms resolved after discontinuation of angiotensin II receptor antagonist. If intestinal angioedema is diagnosed, treatment should be discontinued and appropriate monitoring should be conducted until symptoms completely resolve.
6. Interaction
1) There were no clinically significant drug interactions.
There have been clinical trials examining interactions with cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorthiazide, amlodipine, and glibenclamide. When combined with cimetidine, the systemic exposure of valsartan may be increased, and when combined with glibenclamide, the systemic exposure of valsartan may be decreased.
Because this drug is not metabolized to a significant degree, drug-drug interactions due to induction or inhibition of metabolism of the CYP-450 enzyme system are not expected to occur clinically. Although this drug showed high binding to plasma proteins, in vivo studies showed no interaction with highly protein-bound drugs such as diclofenac, furosemide, and warfarin.
2) When using potassium-sparing diuretics (spironolactone, triamterene, amirolide), potassium supplements, potassium-containing salts, or drugs that can increase potassium concentration (e.g., heparin), caution is required as blood potassium concentration may increase or blood creatinine concentration may increase in heart failure patients.
3) When angiotensin II receptor antagonists are used in combination with non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day), non-selective NSAIDs), the blood pressure lowering effect may be reduced. Like ACE inhibitors, combined use of angiotensin II receptor antagonists and NSAIDs can worsen renal function, cause acute renal failure, and increase serum potassium. Caution must be exercised when using together, especially in the elderly or patients with reduced effective blood volume (including patients receiving diuretic treatment). After starting combination treatment, patients should be provided with adequate fluids and renal function should be monitored periodically.
4) A reversible increase in serum lithium concentration and toxicity has been reported with co-administration of lithium drugs and ACE inhibitors or angiotensin II receptor antagonists, including this drug. Therefore, monitoring of serum lithium concentrations is recommended during coadministration. The risk of lithium toxicity may increase if thiazide diuretics are additionally used.
5) Transporters: In vitro studies using human liver tissue showed that valsartan is a substrate for the liver uptake transporter OATP1B1 and the liver efflux transporter MRP2. Coadministration with uptake transporter inhibitors (rifampicin, cyclosporine) or efflux transporter inhibitors (ritonavir) may increase systemic exposure of valsartan.
6) Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin receptor antagonists, ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving this drug concomitantly with other drugs that act on RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2).
7. Administration to pregnant and lactating women
1) Because of the mechanism of action of angiotensin II receptor antagonists, the risk to the fetus cannot be ignored. In pregnant women exposed to ACE inhibitors (a specific class of drugs that act on the renin-angiotensin-aldosterone system) during the second or third trimester of pregnancy, they have been associated with fetal and neonatal harm, including fetal and neonatal hypotension, hyperkalemia, neonatal cranial hypoplasia, urinary retention and/or anuria, reversible or irreversible renal failure, intrauterine growth retardation, and death. Oligohydramnios, presumed to be due to decreased fetal renal function, was reported, and oligohydramnios was associated with fetal limb contractures, craniofacial malformations, and pulmonary hypoplasia. Retrospective data suggest that use of ACE inhibitors in the first trimester of pregnancy is associated with a potential risk of birth defects. Additionally, although it is not clear whether this drug is caused by it, there are reports of prematurity, intrauterine growth retardation, and patent ductus arteriosus. There have been reports of spontaneous abortion, oligohydramnios, and renal dysfunction in newborns when pregnant women accidentally took valsartan. Like other drugs that act directly on the renin-angiotensin-aldosterone system, this drug should not be used by women who are pregnant or planning to become pregnant, and if pregnancy is confirmed while taking the drug, the drug should be discontinued immediately. When prescribing drugs that act on the renin-angiotensin-aldosterone system to women who may become pregnant, doctors should inform them of the potential risks of these drugs during pregnancy. If a pregnant woman has been exposed to angiotensin II receptor antagonists beyond the second trimester, fetal renal function and cranial ultrasound examination is recommended. Additionally, neonates who have been exposed to this drug in utero should be closely monitored for sufficient urination, hyperkalemia, and blood pressure.
2) It is not known whether this drug is secreted in breast milk, but in experiments on rats, secretion of this drug in breast milk was confirmed, so it is not recommended for nursing mothers to use this drug. Avoid administering this drug to breastfeeding women, and if administration is unavoidable, breast-feeding should be discontinued.
3) There is no information about the effects of this drug on human fertility. Studies in rats showed no effects of valsartan on fertility.
8. Administration to children
Safety and efficacy in children and adolescents under 18 years of age have not been established.
9. Administration to elderly people
In the case of elderly people, it is generally considered undesirable to lower blood pressure excessively due to the risk of cerebral infarction, etc., so administration should be done carefully while observing the patient's condition, such as starting from a low dose. Pharmacokinetic tests on elderly people showed that the blood concentration of this drug was higher than that of non-elderly people.
10. Treatment in case of overdose
Although there is no experience with overdose of this drug, significant hypotension, decreased consciousness, circulatory collapse and shock, tachycardia, and bradycardia due to parasympathetic nerve stimulation are expected. Immediately after taking the drug, induce vomiting or administer medicinal charcoal. Otherwise, inject physiological saline into a vein. If low blood pressure occurs, the patient should be placed in a supine position and blood volume should be corrected. Hemodialysis does not help.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
12. Others
In preclinical safety tests using multiple species of animals, no systemic toxicity or toxicity to specific organs was observed, except for reproductive toxicity. A decreased survival rate and a slight delay in physical development were observed in the offspring of rats administered 600 mg/kg/day during the last 3 months of pregnancy and lactation. Preclinical safety results were mainly consistent with the pharmacological properties of the drug and had no clinical significance. Mutagenicity, chromosomal abnormality, and carcinogenicity were not observed.
5. How to save
Store in an airtight container below 30℃, avoiding heat and moisture.
6. Packaging unit
30 tablets/bottle
7. Expiration date
36 months from date of manufacture
Product Updates
Total 4items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 4 | Valtrep Tab. 160mg | Precautions for use | 2026.02.12 | PDF0440_200810522_Precautions for use_Waltrep tablet 160mg.pdf |
| 3 | Valtrep Tab. 160mg | Valtrep tablets 160 mg (precautions for use) | 2017.01.18 | HWPValsartan single tablet system unification adjustment plan.hwp |
| 2 | Valtrep Tab. 160mg | Valtrep Tablet 160mg (Precautions for use) | 2013.01.30 | HWPValtrep Tablet 160mg_Permission changes.hwp |
| 1 | Valtrep Tab. 160mg | Valtrep Tablet 160mg (effectiveness, dosage, usage instructions... | 2012.12.31 | HWPValtrep Tablet 160mg_Permission change order.hwp |